AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22261507 — intervention group
Group type: COMPARATOR
Intervention: Height ≥-1 SD
Number of subjects: 119
Study 22261507 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with normal height
Number of subjects: 119
Study 22261507 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm-born children with normal height
Number of subjects: 119
Study 22262746 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, titrated to tolerability to achieve target trough concentrations of 5-15 ng/mL
Number of subjects: 20
Study 22262746 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 20
Study 22262746 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreatment cohort)
Number of subjects: 20
Study 22263035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP)
Number of subjects: 5000
Study 22263035 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5000
Study 22263047 — intervention group
Group type: EXPERIMENTAL
Intervention: CP + ASA404 (1200 mg/m(2) or 1800 mg/m(2))
Number of subjects: 108
Study 22263047 — intervention group
Group type: COMPARATOR
Intervention: CP alone (Carboplatin AUC 6 mg/ml•min and Paclitaxel 175 mg/m(2))
Number of subjects: 108
Study 22264202 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroFlo catheter treatment
Number of subjects: 26
Study 22264765 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH-treated OMS
Number of subjects: 0
Study 22264765 — intervention group
Group type: COMPARATOR
Intervention: Untreated OMS
Number of subjects: 0
Study 22264765 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL12
Number of subjects: 0
Study 22264765 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR5+ memory B cells
Number of subjects: 0
Study 22264765 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL13 and CXCL12
Number of subjects: 0
Study 22264850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept in the VITAL trial for advanced non-small cell lung cancer
Number of subjects: 0
Study 22264850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept in the VANILLA trial for metastatic pancreatic cancer
Number of subjects: 0
Study 22264850 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI in the VELOUR trial for metastatic colorectal cancer
Number of subjects: 0
Study 22265115 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 1035
Study 22267606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (100 mg fixed dose for 4 weekly infusions) with a short course of steroids
Number of subjects: 23
Study 22267607 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg intravenous loading dose followed by 2 mg/kg weekly)
Number of subjects: 15
Study 22267687 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 400/25 μg once daily for 4 weeks
Number of subjects: 60
Study 22267687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22267750 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced cardiac magnetic resonance to quantify heterogeneous myocardial tissue (gray zone) and dense core scar, along with serum high-sensitivity C-reactive protein (hsCRP) levels
Number of subjects: 235
Study 22267750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile for both GZ and hsCRP (n=42)
Number of subjects: 235
Study 22267750 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile for both GZ and hsCRP (n=32)
Number of subjects: 235
Study 22267829 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% human albumin at 1.25 g/kg/day for 7 days (Tier 2)
Number of subjects: 47
Study 22267829 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% human albumin at 0.625 g/kg/day for 7 days (Tier 1)
Number of subjects: 47
Study 22267829 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% human albumin at 1.875 g/kg/day for 7 days (Tier 3)
Number of subjects: 47
Study 22267829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (upcoming in ALISAH II trial)
Number of subjects: 47
Study 22268134 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with ILA
Number of subjects: 2416
Study 22269066 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT system (electronic health record-embedded tool for shared goal setting)
Number of subjects: 0
Study 22269066 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT system
Number of subjects: 0
Study 22269593 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention enhanced with positive-affect induction and self-affirmation
Number of subjects: 258
Study 22269593 — intervention group
Group type: COMPARATOR
Intervention: Educational protocol alone (control)
Number of subjects: 258
Study 22269735 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel cessation
Number of subjects: 1
Study 22269834 — intervention group
Group type: EXPERIMENTAL
Intervention: MI embedded into physiotherapy (EG1)
Number of subjects: 39
Study 22269834 — intervention group
Group type: EXPERIMENTAL
Intervention: MI added to physiotherapy (EG2)
Number of subjects: 39
Study 22269834 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 39
Study 22269862 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell depletion with rituximab
Number of subjects: 0
Study 22269862 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell modulators such as belimumab and abatacept
Number of subjects: 0
Study 22270258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 31
Study 22270330 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (500 ug daily for 4 days starting 24 hours after each chemotherapy cycle)
Number of subjects: 20
Study 22270330 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 20
Study 22270480 — intervention group
Group type: EXPERIMENTAL
Intervention: copd-6 device
Number of subjects: 305
Study 22270480 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic spirometry
Number of subjects: 305
Study 22271896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and anti-CD20 monoclonal antibody (rituximab and Iodine I-131 tositumomab)
Number of subjects: 142
Study 22271896 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 142
Study 22272248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (three infusions per week)
Number of subjects: 14
Study 22272248 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of gemcitabine and erlotinib
Number of subjects: 14
Study 22272830 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic variant GSTP1 (Ile105Val)
Number of subjects: 57
Study 22273029 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP~T vaccine booster
Number of subjects: 182
Study 22274724 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary control coping (e.g., problem solving)
Number of subjects: 327
Study 22274724 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary control coping (e.g., acceptance)
Number of subjects: 327
Study 22274724 — intervention group
Group type: EXPERIMENTAL
Intervention: Disengagement coping (e.g., avoidance)
Number of subjects: 327
Study 22274724 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 327
Study 22274724 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 327
Study 22274965 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified aspiration (group B, n=93)
Number of subjects: 159
Study 22274965 — intervention group
Group type: COMPARATOR
Intervention: Traditional aspiration (group A, n=66)
Number of subjects: 159
Study 22275401 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP (5 × 10^10 viral particles and above)
Number of subjects: 54
Study 22275401 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP followed by MVA ME-TRAP booster
Number of subjects: 54
Study 22275401 — intervention group
Group type: COMPARATOR
Intervention: ChAd63 ME-TRAP
Number of subjects: 54
Study 22276954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone
Number of subjects: 0
Study 22276954 — intervention group
Group type: COMPARATOR
Intervention: Injectable diacetylmorphine or injectable hydromorphone
Number of subjects: 0
Study 22277551 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine-derived n-3 PUFAs (highest quintile of intake)
Number of subjects: 3166
Study 22277551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of α-linolenic acid
Number of subjects: 3166
Study 22277551 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine-derived n-3 PUFAs
Number of subjects: 3166
Study 22277551 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFAs
Number of subjects: 3166
Study 22277685 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin T (cTnT) ≥0.01 ng/mL
Number of subjects: 254
Study 22277685 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired renal function (chronic kidney disease stage 3-5)
Number of subjects: 254
Study 22277685 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cTnT
Number of subjects: 254
Study 22277685 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality and amputation rates
Number of subjects: 254
Study 22280805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated external beam radiotherapy (55 Gy in 16 fractions at 3.4 Gy per fraction)
Number of subjects: 73
Study 22280813 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (200mg daily orally for 3 months)
Number of subjects: 8
Study 22281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac imaging (single-photon emission computed tomography, positron emission tomography, or 64-slice coronary computed tomography angiography)
Number of subjects: 1703
Study 22281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography
Number of subjects: 1703
Study 22281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac imaging
Number of subjects: 1703
Study 22281388 — intervention group
Group type: EXPERIMENTAL
Intervention: hESC-derived retinal pigment epithelium (RPE) transplantation
Number of subjects: 2
Study 22281797 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival from time of diagnostic right-sided heart catheterization
Number of subjects: 2635
Study 22281797 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic/familial PAH survival rates
Number of subjects: 2635
Study 22281797 — intervention group
Group type: COMPARATOR
Intervention: Estimated survival rates using NIH equation
Number of subjects: 2635
Study 22281831 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (5 × 10^7 plaque-forming units)
Number of subjects: 48
Study 22282182 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography (SW)
Number of subjects: 939
Study 22282182 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual color stiffness assessment
Number of subjects: 939
Study 22282182 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative maximum elasticity of 80 kPa (5.2 m/sec) or less
Number of subjects: 939
Study 22282683 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 84
Study 22282683 — intervention group
Group type: COMPARATOR
Intervention: G+GM
Number of subjects: 84
Study 22282683 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF and G+GM
Number of subjects: 84
Study 22283499 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum women with major depression
Number of subjects: 120
Study 22284809 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β1
Number of subjects: 64
Study 22284809 — intervention group
Group type: COMPARATOR
Intervention: Silencing TGF-β1 receptors
Number of subjects: 64
Study 22284935 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer threshold < 1000 ng mL(-1) with RGS ≤ 6
Number of subjects: 678
Study 22284935 — intervention group
Group type: COMPARATOR
Intervention: D-dimer threshold < 500 ng mL(-1) with RGS ≤ 6
Number of subjects: 678
Study 22285014 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 275
Study 22285199 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 149
Study 22285963 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily) for 9 months
Number of subjects: 41
Study 22286551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 21
Study 22286779 — intervention group
Group type: EXPERIMENTAL
Intervention: S9 CPAP
Number of subjects: 50
Study 22286779 — intervention group
Group type: COMPARATOR
Intervention: Usual CPAP pre-S9
Number of subjects: 50
Study 22287426 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) coupled with continued medical management
Number of subjects: 180
Study 22287426 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 180
Study 22289660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs) (100-400 × 10(6) cells)
Number of subjects: 20
Study 22289660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs)
Number of subjects: 20
Study 22289724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 25 μg, 50 μg, 100 μg, and 200 μg
Number of subjects: 19
Study 22289893 — intervention group
Group type: EXPERIMENTAL
Intervention: Costimulated tumor-derived donor lymphocyte (TDL) infusion
Number of subjects: 8
Study 22291430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise stress echocardiography in patients with HFPEF
Number of subjects: 21
Study 22291430 — intervention group
Group type: COMPARATOR
Intervention: Sub-maximal exercise stress echocardiography in controls
Number of subjects: 21
Study 22291430 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of LV afterload (arterial elastance) during exercise
Number of subjects: 21
Study 22291490 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril (5 mg/daily)
Number of subjects: 33
Study 22291490 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/daily)
Number of subjects: 33
Study 22291490 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 22292502 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 305
Study 22292502 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist/height ratio (WHtR)
Number of subjects: 305
Study 22292502 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 305
Study 22292502 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage (BFP)
Number of subjects: 305
Study 22292853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone (Len + Dex)
Number of subjects: 63
Study 22293175 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-743
Number of subjects: 1
Study 22293175 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARγ agonists
Number of subjects: 1
Study 22293660 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244) 75 mg twice daily
Number of subjects: 1
Study 22294344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 1-5 mg/kg/day for at least 36 months
Number of subjects: 26
Study 22296955 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402
Number of subjects: 0
Study 22296955 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 0
Study 22296967 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental sexual abuse
Number of subjects: 106
Study 22297835 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI)
Number of subjects: 1008
Study 22297835 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial infections
Number of subjects: 1008
Study 22297835 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep infections
Number of subjects: 1008
Study 22297835 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection locations
Number of subjects: 1008
Study 22297835 — intervention group
Group type: COMPARATOR
Intervention: Wound contamination classification and duration of operation
Number of subjects: 1008
Study 22298167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine infused to achieve 80% of the maximum heart rate response for age
Number of subjects: 167
Study 22298637 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive urine dipstick test (UDT) combined with estimated glomerular filtration rate (eGFR)
Number of subjects: 2465
Study 22298637 — intervention group
Group type: COMPARATOR
Intervention: Negative urine dipstick test (UDT)
Number of subjects: 2465
Study 22298797 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 30
Study 22298944 — intervention group
Group type: EXPERIMENTAL
Intervention: RebiSmart™ electronic auto-injector for subcutaneous IFN β-1a
Number of subjects: 63
Study 22298950 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (1 mg/5 mL), 0.02-0.1 mg/kg three times a day; n = 20
Number of subjects: 38
Study 22298950 — intervention group
Group type: COMPARATOR
Intervention: Placebo; n = 18
Number of subjects: 38
Study 22298950 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 38
Study 22298950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22300423 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily)
Number of subjects: 196
Study 22300696 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medication
Number of subjects: 1803
Study 22300696 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model based on echocardiographic values
Number of subjects: 1803
Study 22300696 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria for SCD risk
Number of subjects: 1803
Study 22300696 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of SCD
Number of subjects: 1803
Study 22300740 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized algorithm incorporating cinacalcet and active vitamin D
Number of subjects: 92
Study 22302299 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation (PNS) using Eupnea System device at a maximum of 10 mA
Number of subjects: 19
Study 22302349 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg daily, gemcitabine 1,000 mg/m2, cisplatin 25 mg/m2 administered on days 1 and 8 every 3 weeks.
Number of subjects: 22
Study 22302620 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Number of subjects: 72
Study 22302620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Change for Diabetes Prevention
Number of subjects: 72
Study 22302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels >0.21 ng/mL without antibiotic treatment
Number of subjects: 1641
Study 22302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels <0.05 ng/mL without antibiotic treatment
Number of subjects: 1641
Study 22302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physician estimates and PCT values
Number of subjects: 1641
Study 22302662 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT model alone
Number of subjects: 1641
Study 22304793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (dosage not specified)
Number of subjects: 40600
Study 22304793 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg
Number of subjects: 40600
Study 22304793 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 40600
Study 22304793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40600
Study 22305169 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax drink (3/day)
Number of subjects: 17
Study 22305169 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax bread (3/day)
Number of subjects: 17
Study 22305169 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low-fiber)
Number of subjects: 17
Study 22305329 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Triage and Acuity Scale
Number of subjects: 1464
Study 22305344 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) with implants; no specific dosage or duration mentioned.
Number of subjects: 6
Study 22305344 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) with IPG replacement; no specific dosage or duration mentioned.
Number of subjects: 6
Study 22306782 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80-160 mg
Number of subjects: 38
Study 22306849 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated tool for assessing retinal vessel caliber (AVIx calculator)
Number of subjects: 210
Study 22307813 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite varus thrust
Number of subjects: 82
Study 22307813 — intervention group
Group type: COMPARATOR
Intervention: No definite varus thrust
Number of subjects: 82
Study 22307813 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus alignment
Number of subjects: 82
Study 22307813 — intervention group
Group type: COMPARATOR
Intervention: No varus alignment
Number of subjects: 82
Study 22308041 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic-euglycemic plus intralipid and heparin
Number of subjects: 18
Study 22308041 — intervention group
Group type: COMPARATOR
Intervention: saline infusion (SAL)
Number of subjects: 18
Study 22308240 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reading algorithm (SEA-AF)
Number of subjects: 346
Study 22308240 — intervention group
Group type: COMPARATOR
Intervention: Standard telemetry without structured reading
Number of subjects: 346
Study 22308240 — intervention group
Group type: COMPARATOR
Intervention: Daily electrocardiographic assessments
Number of subjects: 346
Study 22308288 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20-specific CAR T-cell infusion after cyclophosphamide lymphodepletion
Number of subjects: 4
Study 22308288 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20-specific CAR T-cell infusion
Number of subjects: 4